Diagnosis of pancreatobiliary cancer by measuring the urinary and serum levels of porphyrins after oral administration of 5-aminolevulinic acid.
Not Applicable
- Conditions
- Patients who have suspected pancreatobiliary disease.
- Registration Number
- JPRN-UMIN000018114
- Lead Sponsor
- Kansai Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 67
Inclusion Criteria
Not provided
Exclusion Criteria
1.Patients with porphyria. 2.Patients with hypersensitivity to 5-aminolevulinic acid or porphyrins. 3.In cases of known or suspected pregnancy or woman who are breast-feeding. 4.Patients who doctors regard as inappropriate ones for the enrollment due to some reasons.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The urinary and serum levels of porphyrins after oral administration of 5-aminolevulinic acid in pancreaticobiliary lesions.
- Secondary Outcome Measures
Name Time Method